Evidence map›Paper›PMID 30255820›Full record

ArticleBMC genetics2018

Detecting responses to treatment with fenofibrate in pedigrees.

Svetlana Cherlin, Maggie Haitian Wang, Heike Bickeböller, Rita M Cantor

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC genetics, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 4 institutions in 4 countries.

Svetlana CherlinInstitute of Genetic Medicine, International Centre for Life, Newcastle University, Central Parkway, Newcastle upon Tyne, NE1 3BZ, UK.
Maggie Haitian WangDivision of Biostatistics, Centre for Clinical Research and Biostatistics, JC School of Public Health and Primary Care, The Chinese University of Hong Kong, Shatin, N.T., Hong Kong SAR, China.
Heike BickeböllerDepartment of Genetic Epidemiology, University Medical Center, Georg-August University Göttingen, Humboldtallee 32, 37073, Göttingen, Germany.
Rita M CantorDepartment of Human Genetics, David Geffen School of Medicine at UCLA, 695 Charles E. Young Dr. South, Los Angeles, CA, 90095, USA. rcantor@mednet.ucla.edu.
Chinese University of Hong Kong · CNNewcastle University · GBUniversity of California, Los Angeles · USUniversity of Göttingen · DE

Funding

Systems genomics of metabolic syndrome traitsP01HL028481 · NHLBI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI LUSIS, ALDONS JAKE · 1985 to 2019
$50.2M
Genetic and Environmental Determinants of TriglyceridesU01HL072524 · NHLBI · UNIVERSITY OF MINNESOTA TWIN CITIES · PI ARNETT, DONNA K · 2002 to 2008
$11.9M
GENETIC ANALYSIS OF COMMON DISEASES: AN EVALUATIONR01GM031575 · NIGMS · UNIVERSITY OF TEXAS RIO GRANDE VALLEY · PI ALMASY, LAURA A. · 1985 to 2016
$7.8M
Genomewide Association Study of Lipid Response to Fenofibrate and Dietary FatR01HL091357 · NHLBI · UNIVERSITY OF KENTUCKY · PI ARNETT, DONNA K · 2008 to 2018
$5.8M
Epigenetic Determinants of Lipid Response to Dietary Fat and FenofibrateR01HL104135 · NHLBI · UNIVERSITY OF KENTUCKY · PI ARNETT, DONNA K · 2010 to 2015
$5.5M
Arthritis Research UK MR-K015346Medical Research Council MR-K015346NHLBI NIH HHS P01 HL028481NHLBI NIH HHS R01 HL091357NHLBI NIH HHS R01 HL104135NHLBI NIH HHS U01 HL072524NIGMS NIH HHS R01 GM031575Wellcome TrustWellcome Trust 102858/Z/13/Z
6 · The paper itself

Abstract

backgroundFenofibrate (Fb) is a known treatment for elevated triglyceride (TG) levels. The Genetics of Lipid Lowering Drugs and Diet Network (GOLDN) study was designed to investigate potential contributors to the effects of Fb on TG levels. Here, we summarize the analyses of 8 papers whose authors had access to the GOLDN data and were grouped together because they pursued investigations into Fb treatment responses as part of GAW20. These papers report explorations of a variety of genetics, epigenetics, and study design questions. Data regarding treatment with 160 mg of micronized Fb per day for 3 weeks included pretreatment and posttreatment TG and methylation levels (ML) at approximately 450,000 epigenetic markers (cytosine-phosphate-guanine [CpG] sites). In addition, approximately 1 million single-nucleotide polymorphisms (SNPs) were genotyped or imputed in each of the study participants, drawn from 188 pedigrees.

resultsThe analyses of a variety of subsets of the GOLDN data used a number of analytic approaches such as linear mixed models, a kernel score test, penalized regression, and artificial neural networks.

conclusionsResults indicate that (a) CpG ML are responsive to Fb; (b) CpG ML should be included in models predicting the TG level responses to Fb;

Indexed as

CpG IslandsDNA MethylationDrug Administration ScheduleEpigenomicsFenofibrateGenome-Wide Association StudyHumansHypertriglyceridemiaHypolipidemic AgentsLinear ModelsNeural Networks, ComputerPolymorphism, Single NucleotideQuantitative Trait LociTriglyceridesFenofibrateHypolipidemic AgentsTriglyceridesEpigeneticsFenofibrate treatmentGOLDN studyPredictive modelingTriglycerides

Identifiers

PMID30255820
PMCPMC6156837
OpenAlexW2892013481

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.